Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.

(2009) · PubMed Central · Cited by 44,859 · see citing works

Meta-analysis in clinical trials

DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554 · see citing works

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575 · see citing works

Schizophrenia

van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971 · see citing works

Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects

Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742 · see citing works

Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review

Potvin, S., Stip, É., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, É. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.024 · Cited by 989 · see citing works

Abnormal gray and white matter volume in delusional infestation

Wolf, R. C., Huber, M. K., Depping, M. S., Thomann, P. A., Kärner, M., Lepping, P., & Freudenmann, R. W. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.004 · Cited by 606 · see citing works

The genetics of schizophrenia and bipolar disorder: dissecting psychosis

Craddock, N., O’Donovan, M. C., & Owen, M. J. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.030718 · Cited by 574 · see citing works

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · see citing works

Cytokines and schizophrenia: microglia hypothesis of schizophrenia

Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508 · see citing works

Epidemiology of Schizophrenia

Häfner, H., & der Heiden, W. A. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200204 · Cited by 437 · see citing works

Season of birth in schizophrenia: A review of evidence, methodology, and etiology.

Bradbury, T. N., & Miller, G. A. (1985) · Psychological Bulletin · doi:10.1037/0033-2909.98.3.569 · Cited by 344 · see citing works

The Role of Immune System in Schizophrenia

Müller, N., & Schwarz, M. (2010) · Current Immunology Reviews · doi:10.2174/157339510791823673 · Cited by 297 · see citing works

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

Chaudhry, I. B., Hallak, J. E. C., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S. M., Dunn, G., & Deakin, J. F. W. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 281 · see citing works

Cytokines in schizophrenia and the effects of antipsychotic drugs

Drzyzga, Ł. R., Obuchowicz, E., Marcinowska, A., & Herman, Z. S. (2006) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2006.02.002 · Cited by 242 · see citing works

Metabolic profile of antipsychotic-naive individuals with non-affective psychosis

Fernández-Egea, E., Bernardo, M., Donner, T. W., Conget, I., Parellada, E., Justicia, A., Esmatjes, E., García‐Rizo, C., & Kirkpatrick, B. W. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.052605 · Cited by 242 · see citing works

One year outcome in first episode psychosis: influence of DUP and other predictors

MALLA, A. K. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00254-7 · Cited by 234 · see citing works

The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence

Smith, R. S., & Maes, M. H. J. (1995) · Medical Hypotheses · doi:10.1016/0306-9877(95)90062-4 · Cited by 222 · see citing works

Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness

Ganguli, R., Yang, Z., Shurin, G. V., Chengappa, K. N. R., Brar, J. S., Gubbi, A. V., & Rabin, B. S. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90042-6 · Cited by 222 · see citing works

Serum and gene expression profile of cytokines in first-episode psychosis

Di Nicola, M., Cattaneo, A., Hepgul, N., Di Forti, M., Aitchison, K. J., Janiri, L., Murray, R. M., Dazzan, P., Pariante, C. M., & Mondelli, V. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.06.010 · Cited by 217 · see citing works

The evolution of depression and suicidality in first episode psychosis

Upthegrove, R., Birchwood, M. J., Ross, K., Brunett, K., McCollum, R., & Jones, L. A. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01506.x · Cited by 214 · see citing works

Inflammatory Cytokines and Neurological and Neurocognitive Alterations in the Course of Schizophrenia

Fineberg, A. M., & Ellman, L. M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.001 · Cited by 200 · see citing works

Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients

Theodoropoulou, S., Spanakos, G., Baxevanis, C. N., Economou, M., Gritzapis, A. D., Papamichail, M., & Stefanis, C. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00007-4 · Cited by 187 · see citing works

Th1, Th2 and Th3 cytokine alteration in schizophrenia

Kim, Y., Myint, A.-M., Lee, B.-H., Han, C.-S., Lee, H., Kim, D.-J., & Leonard, B. E. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.047 · Cited by 187 · see citing works

The Interaction of Nuclear Factor-Kappa B and Cytokines Is Associated with Schizophrenia

Song, X., Lv, L., Li, W., Hao, Y., & Zhao, J. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.018 · Cited by 187 · see citing works

Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics

Kim, Y., Kim, L., & Lee, M. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00171-1 · Cited by 159 · see citing works

The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-γ

Bian, Q., Kato, T. A., Monji, A., Hashioka, S., Mizoguchi, Y., Horikawa, H., & Kanba, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.06.031 · Cited by 155 · see citing works

Immune dysregulation and self‐reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?

Jones, A. L., Mowry, B. J., Pender, M. P., & Greer, J. M. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01305.x · Cited by 155 · see citing works

Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse

Borovčanin, M., Jovanović, I., Radosavljevic, G. D., Dejanovic, S. D., Banković, D., Arsenijević, N., & Lukić, M. L. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.016 · Cited by 151 · see citing works

Elevated Levels of Soluble Interleukin 2 Receptors in Schizophrenia

Rapaport, M. H. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810030097017 · Cited by 144 · see citing works

The American Psychiatric Publishing Textbook of Schizophrenia

(2007) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e318033a46f · Cited by 138 · see citing works

Season of Birth in Schizophrenia

O’Callaghan, E., Gibson, T., Colohan, H. A., Walshe, D. G., Buckley, P., Larkin, C., & Waddington, J. L. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.6.764 · Cited by 138 · see citing works

Cytokine Changes and Tryptophan Metabolites in Medication-Naïve and Medication-Free Schizophrenic Patients

Kim, Y., Myint, A.-M., Verkerk, R. M., Scharpé, S., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Neuropsychobiology · doi:10.1159/000213565 · Cited by 136 · see citing works

Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia

Kowalski, J., Blada, P., Kucia, K. A., Madej, A., & Herman, Z. S. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00156-0 · Cited by 128 · see citing works

Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls

Reale, M., Patruno, A., Lutiis, M. A. D., Pesce, M., Felaco, M., Giannantonio, M. D., Nicola, M. D., & Grilli, A. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-13 · Cited by 126 · see citing works

Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration

Akiyama, K. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00140-6 · Cited by 109 · see citing works

The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view

Müller, N., & Schwarz, M. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_33 · Cited by 107 · see citing works

Serum‐soluble interleukin‐2 receptors in neuroleptic‐naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia

Rapaport, M. H., & Lohr, J. B. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01599.x · Cited by 99 · see citing works

Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features

García‐Rizo, C., Fernández-Egea, E., Oliveira, C., Justicia, A., Bernardo, M., & Kirkpatrick, B. W. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.08.014 · Cited by 90 · see citing works

Cytokine profiles in schizophrenic patients treated with risperidone

Cazzullo, C. L., Sacchetti, E., Galluzzo, A., Panariello, A., Adorni, A., Pegoraro, M., Bosis, S., Colombo, F., Trabattoni, D., Zagliani, A., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00221-4 · Cited by 89 · see citing works

Close encounters of the monoamine kind: immune cells betray their nervous disposition

Meredith, E. J., Chamba, A., Holder, M. J., Barnes, N. M., & Gordon, J. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02166.x · Cited by 83 · see citing works

Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response

Borovčanin, M., Jovanović, I., Radosavljevic, G. D., Dejanovic, S. D., Stefanović, V., Arsenijević, N., & Lukić, M. L. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.027 · Cited by 82 · see citing works

Cytokine profiles in drug-naive schizophrenic patients

Cazzullo, C. L., Sacchetti, E., Galluzzo, A., Panariello, A., Colombo, F., Zagliani, A., & Clerici, M. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00046-3 · Cited by 80 · see citing works

Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model

Seki, Y., Kato, T. A., Monji, A., Mizoguchi, Y., Horikawa, H., Sato‐Kasai, M., Yoshiga, D., & Kanba, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.09.011 · Cited by 72 · see citing works

Abnormalities in serum concentrations of interleukin-2, interferon-α and interferon-γ in schizophrenia not detected

Gattaz, W. F., Dalgalarrondo, P., & Schröder, H. C. (1992) · Schizophrenia Research · doi:10.1016/0920-9964(92)90006-q · Cited by 64 · see citing works

Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: Implication for antioxidative psychotropic actions via microglia

Kato, T. A., Monji, A., Yasukawa, K., Mizoguchi, Y., Horikawa, H., Seki, Y., Hashioka, S., Han, Y.-H., Kasai, M., Sonoda, N., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.019 · Cited by 62 · see citing works

Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: Effects of antipsychotic drugs

Crespo‐Facorro, B., Carrasco-Marı́n, E., Pérez‐Iglesias, R., Pelayo‐Terán, J. M., Fernández-Prieto, L., Leyva‐Cobián, F., & Vázquez‐Barquero, J. L. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2006.08.005 · Cited by 55 · see citing works

Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology

Xiu, M. H., Chen, D. C., Wang, D., Zhang, K., Dong, A., Tang, W., Zhang, F., Liu, L. J., Liu, J. H., Liu, H. B., et al. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.04.026 · Cited by 53 · see citing works

The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia

Xiong, P., Zeng, Y., Wan, J., XiaoHan, D. H., Tan, D., Lü, J., Xu, F., Li, H. Y., Zhu, Z., & Ma, M. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2010.12.017 · Cited by 52 · see citing works

Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients

Sirota, P., Meiman, M. E., Hershko, R., & Bessler, H. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.04.012 · Cited by 51 · see citing works

Serum Interferon in First Psychotic Attack

Becker, D., Kritschmann, E., Floru, S., Shlomo-David, Y., & Gotlieb‐Stematsky, T. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.157.1.136 · Cited by 31 · see citing works

The immune system and schizophrenia: an update for clinicians

Upthegrove, R., & Barnes, N. M. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.113.011452 · Cited by 26 · see citing works

Neuropsychiatric Disorders: An Integrative Approach

(2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1048 · Cited by 25 · see citing works

Neuropsychiatric Disorders An Integrative Approach

Gerlach, M., Koutsilieri, E., Double, K. L., & Deckert, J. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9 · Cited by 19 · see citing works

Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients

Xiu, M., CHEN, S., WANG, F., Cao, L., Qi, L. Y., CHEN, D., Wu, G. Y., Lü, L., Kosten, T. A., & KOSTEN, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.001 · Cited by 11 · see citing works

A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683 · see citing works

Maternal immune activation and abnormal brain development across CNS disorders

Knuesel, I., Chicha, L., Britschgi, M., Schobel, S. A., Bodmer, M., Hellings, J. A., Toovey, S., & Prinssen, E. P. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.187 · Cited by 880 · see citing works

Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment

Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926 · see citing works

The intriguing relationship between coronary heart disease and mental disorders

Binder, M. D., Detraux, J., & Vancampfort, D. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/mdehert · Cited by 492 · see citing works

Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses

Yuan, N., Chen, Y., Xia, Y., Dai, J., & Liu, C. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0570-y · Cited by 428 · see citing works

Depression and Schizophrenia: Cause, Consequence or Trans-diagnostic Issue?

Upthegrove, R., Marwaha, S., & Birchwood, M. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw097 · Cited by 400 · see citing works

Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders

Williams, J. A., Burgess, S., Suckling, J., Lalousis, P. A., Batool, F., Griffiths, S. L., Palmer, E. R., Karwath, A., Barsky, A., Gkoutos, G. V., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.0407 · Cited by 310 · see citing works

Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization

Howes, O. D., & McCutcheon, R. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.278 · Cited by 288 · see citing works

Cytokine Alterations in Schizophrenia: An Updated Review

Momtazmanesh, S., Zare-Shahabadi, A., & Rezaei, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00892 · Cited by 277 · see citing works

Cross talk: the microbiota and neurodevelopmental disorders

Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271 · see citing works

The kynurenine pathway in schizophrenia and bipolar disorder

Erhardt, S., Schwieler, L., Imbeault, S., & Engberg, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.020 · Cited by 257 · see citing works

Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

Plitman, E., Iwata, Y., Caravaggio, F., Nakajima, S., Chung, J. K., Gerretsen, P., Kim, J., Takeuchi, H., Chakravarty, M. M., Remington, G. J., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw221 · Cited by 252 · see citing works

Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models

Pillinger, T., D’Ambrosio, E., McCutcheon, R., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0058-9 · Cited by 230 · see citing works

Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia

Upthegrove, R., & Khandaker, G. M. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2018_88 · Cited by 230 · see citing works

Neuroinflammation in schizophrenia: meta-analysis of <i>in vivo</i> microglial imaging studies

Marques, T. R., Ashok, A. H., Pillinger, T., Veronese, M., Turkheimer, F. E., Dazzan, P., Sommer, I. E. C., & Howes, O. D. (2019) · Psychological Medicine · doi:10.1017/s0033291718003057 · Cited by 213 · see citing works

An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis

Çakici, N., van Beveren, N. J. M., Judge-Hundal, G., Koola, M. M., & Sommer, I. E. (2019) · Psychological Medicine · doi:10.1017/s0033291719001995 · Cited by 215 · see citing works

A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis

Pillinger, T., Osimo, E. F., Brugger, S., Mondelli, V., McCutcheon, R. A., & Howes, O. D. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby160 · Cited by 190 · see citing works

Immunopsychiatry: important facts

Khandaker, G. M., Dantzer, R., & Jones, P. B. (2017) · Psychological Medicine · doi:10.1017/s0033291717000745 · Cited by 200 · see citing works

Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health

Raony, Í., de Figueiredo, C. S., Pandolfo, P., Giestal-de-Araujo, E., Oliveira-Silva Bomfim, P., & Savino, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01170 · Cited by 185 · see citing works

Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions

Miller, B. J., & Goldsmith, D. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.211 · Cited by 182 · see citing works

Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives

Ermakov, E. A., Melamud, M. M., Buneva, V. N., & Ivanova, S. А. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.880568 · Cited by 184 · see citing works

Profiling inflammatory signatures of schizophrenia: A cross-sectional and meta-analysis study

Frydecka, D., Krzystek‐Korpacka, M., Lubeiro, A., Stramecki, F., Stańczykiewicz, B., Beszłej, J. A., Piotrowski, P., Kotowicz, K., Szewczuk-Bogusławska, M., Pawlak, E., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.05.002 · Cited by 179 · see citing works

Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis

Pillinger, T., Beck, K., Stubbs, B., & Howes, O. D. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.117.200907 · Cited by 170 · see citing works

The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial

Deakin, J. F. W., John Suckling, A., Barnes, T. R. E., Byrne, K., Chaudhry, I. B., Dazzan, P., Drake, R., Giordano, A., Husain, N., Jones, P. B., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30345-6 · Cited by 174 · see citing works

Understanding the Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders

Dash, S., Syed, Y. A., & Khan, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.880544 · Cited by 179 · see citing works

Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis

Karageorgiou, V., Milas, G. P., & Michopoulos, I. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.017 · Cited by 163 · see citing works

Maternal immune activation in neurodevelopmental disorders

Solek, C. M., Farooqi, N., Verly, M., Lim, T. K., & Ruthazer, E. S. (2018) · Developmental Dynamics · doi:10.1002/dvdy.24612 · Cited by 168 · see citing works

Inflammation in first‐episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta‐analysis

Dunleavy, C., Elsworthy, R. J., Upthegrove, R., Wood, S. J., & Aldred, S. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13416 · Cited by 169 · see citing works

In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma

Coughlin, J. M., Wang, Y., Ambinder, E. B., Ward, R. E., Minn, I., Vranešić, M., Kim, P. K., Ford, C. N., Higgs, C. P., Hayes, L. N., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.40 · Cited by 169 · see citing works

Is there a role for immune-to-brain communication in schizophrenia?

Khandaker, G. M., & Dantzer, R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3975-1 · Cited by 169 · see citing works

The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia

Roomruangwong, C., Noto, C. D. S., Kanchanatawan, B., Anderson, G., Kubera, M., Carvalho, A. F., & Maes, M. H. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01737-z · Cited by 162 · see citing works

Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis

Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., Dalm, V. A. S. H., de Haan, L., & van Beveren, N. J. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.039 · Cited by 161 · see citing works

IL-6, IL-18, SIL-2R, and TNFα Proinflammatory Markers in Depression and Schizophrenia Patients Who Are Free of Overt Inflammation

Al-Hakeim, H. K., Al-Rammahi, D. A., & Al-Dujaili, A. H. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.044 · Cited by 152 · see citing works

Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis

Misiak, B., Stańczykiewicz, B., Łaczmański, Ł., & Frydecka, D. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.03.031 · Cited by 151 · see citing works

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial

Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00098-x · Cited by 148 · see citing works

Autism spectrum disorder and schizophrenia: An updated conceptual review

Jutla, A., Foss‐Feig, J. H., & Veenstra-VanderWeele, J. M. (2021) · Autism Research · doi:10.1002/aur.2659 · Cited by 151 · see citing works

Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders

Murray, A., Rogers, J. C., Katshu, M. Z. U. H., Liddle, P. F., & Upthegrove, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.703452 · Cited by 147 · see citing works

Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder

Amare, A. T., Schubert, K. O., Hou, L., Clark, S. R., Papiol, S., Heilbronner, U., Degenhardt, F., Ayele, F. T., Hsu, Y., Shekhtman, T., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3433 · Cited by 157 · see citing works

The complement system in schizophrenia: where are we now and what’s next?

Woo, J., Pouget, J. G., Zai, C. C. H., & Kennedy, J. L. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0479-0 · Cited by 137 · see citing works

Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review

Picker, L. D., Morrens, M., Chance, S. A., & Boche, D. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00238 · Cited by 136 · see citing works

Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials

Cho, M., Lee, T. Y., Kwak, Y. B., Yoon, Y. B., Kim, M., & Kwon, J. S. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835028 · Cited by 128 · see citing works

Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: An electronic health record-based study

Osimo, E. F., Cardinal, R. N., Jones, P. B., & Khandaker, G. M. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.02.031 · Cited by 124 · see citing works

Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study

Metcalf, S. A., Jones, P. B., Nordström, T., Timonen, M., Mäki, P. H., Miettunen, J., Jääskeläinen, E., Järvelin, M., Štochl, J., Murray, G. K., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.09.008 · Cited by 124 · see citing works

Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Plavén‐Sigray, P., Matheson, G. J., Collste, K., Ashok, A. H., Coughlin, J. M., Howes, O. D., Mizrahi, R., Pomper, M. G., Rusjan, P., Veronese, M., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.02.1171 · Cited by 125 · see citing works

Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment

Mongan, D., Ramesar, M., Föcking, M., Cannon, M., & Cotter, D. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12859 · Cited by 123 · see citing works

Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort

Khandaker, G. M., Zammit, S., Burgess, S., Lewis, G., & Jones, P. B. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.11.020 · Cited by 118 · see citing works

Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship

Rodrígues-Amorím, D., Baltanás, T. R., Spuch, C., Caruncho, H. J., González‐Fernández, Á., Olivares, J. M., & Agís‐Balboa, R. C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.023 · Cited by 120 · see citing works

High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance

Noto, C. D. S., Maes, M. H. J., Ota, V., Teixeira, A. L., Bressan, R. A., Gadelha, A., & Brietzke, E. M. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1062552 · Cited by 116 · see citing works

Pathophysiological Role of Purines and Pyrimidines in Neurodevelopment: Unveiling New Pharmacological Approaches to Congenital Brain Diseases

Fumagalli, M., Lecca, D., Abbracchio, M. P., & Ceruti, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00941 · Cited by 116 · see citing works

Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis

Noto, M. N., Maes, M. H. J., Nunes, S. O. V., Ota, V., Rossaneis, A. C., Verri, W. A., Jr., Cordeiro, Q., Belangero, S. I., Gadelha, A., Bressan, R. A., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.12.008 · Cited by 110 · see citing works

The role of the gut microbiome in the development of schizophrenia

Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G. A., & Dinan, T. G. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.010 · Cited by 119 · see citing works

Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits

Goldsmith, D. R., & Rapaport, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00046 · Cited by 110 · see citing works

Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis

Noto, C. D. S., Ota, V., Gouvêa, E. S., Rizzo, L. B., Spíndola, L., Honda, P. H. S., Cordeiro, Q., Belangero, S. I., Bressan, R. A., Gadelha, A., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu042 · Cited by 106 · see citing works

Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis

Gallego, J. A., Blanco, E. A., Husain-Krautter, S., Fagen, E. M., Moreno-Merino, P., del Ojo-Jiménez, J. A., Ahmed, A. O., Rothstein, T. L., Lencz, T., & Malhotra, A. K. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.07.019 · Cited by 107 · see citing works

Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis

Misiak, B., Bartoli, F., Carrà, G., Stańczykiewicz, B., Gładka, A., Frydecka, D., Samochowiec, J., Jarosz, K., Hadryś, T., & Miller, B. J. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105200 · Cited by 107 · see citing works

Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28

Collste, K., Plavén‐Sigray, P., Fatouros‐Bergman, H., Victorsson, P. I., Schain, M., Forsberg, A., Amini, N., Aeinehband, S., Farde, L., Flyckt, L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.247 · Cited by 104 · see citing works

Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence

Mongan, D., Föcking, M., Healy, C., Susai, S. R., Heurich, M., Wynne, K. J., Nelson, B., McGorry, P. D., Amminger, G. P., Nordentoft, M., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2459 · Cited by 102 · see citing works

The Role of Cytokines in the Pathogenesis of Schizophrenia

Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173849 · Cited by 102 · see citing works

In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study

Holmes, S. E., Hinz, R., Drake, R., Gregory, C. J., Conen, S., Matthews, J. C., Anton‐Rodriguez, J., Gerhard, A., & Talbot, P. S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.180 · Cited by 97 · see citing works

Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment

Reale, M., Costantini, E., & Greig, N. H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.536257 · Cited by 98 · see citing works

The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review

Fond, G. B., d’Albis, M.-A., Jamain, S., Tamouza, R., Arango, C., Fleischhacker, W. W., Glenthoj, B. Y., Leweke, F. M., Lewis, S. W., McGuire, P. K., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv002 · Cited by 96 · see citing works

Molecular substrates of schizophrenia: homeostatic signaling to connectivity

Landek‐Salgado, M. A., Faust, T. E., & Sawa, A. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.141 · Cited by 93 · see citing works

Is it time for immunopsychiatry in psychotic disorders?

Leboyer, M., Oliveira, J., Tamouza, R., & Groc, L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4266-1 · Cited by 96 · see citing works

Clinical studies of neuroinflammatory mechanisms in schizophrenia

Watkins, C. C., & Andrews, S. R. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.018 · Cited by 96 · see citing works

Applications of blood-based protein biomarker strategies in the study of psychiatric disorders

Chan, M. K., Gottschalk, M. G., Haenisch, F., Tomasik, J., Ruland, T., Rahmoune, H., Guest, P. C., & Bahn, S. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.08.002 · Cited by 94 · see citing works

Serum kynurenic acid is reduced in affective psychosis

Wurfel, B., Drevets, W., Bliss, S., Mcmillin, J., Suzuki, H., Ford, B., Morris, H., Teague, T., Dantzer, R., & Savitz, J. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.88 · Cited by 92 · see citing works

Greater extracellular free-water in first-episode psychosis predicts better neurocognitive functioning

Lyall, A. E., Pasternak, O., Robinson, D. G., Newell, D., Trampush, J. W., Gallego, J. A., D, M. F. M., Malhotra, A. K., Karlsgodt, K. H., Kubicki, M. R., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.43 · Cited by 91 · see citing works

Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics

Kroken, R. A., Sommer, I. E., Steen, V. M., Dieset, I., & Johnsen, E. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00753 · Cited by 94 · see citing works

Is It Possible to Predict the Future in First-Episode Psychosis?

Suvisaari, J., Mantere, O., Keinänen, J., Mäntylä, T. J. S., Rikandi, E., Lindgren, M., Kieseppä, T., & Raij, T. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00580 · Cited by 88 · see citing works

The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample mendelian randomization study

Perry, B. I., Burgess, S., Jones, H. J., Zammit, S., Upthegrove, R., Mason, A. M., Day, F. R., Langenberg, C., Wareham, N. J., Jones, P. B., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003455 · Cited by 88 · see citing works

The pro‐cognitive mechanisms of physical exercise in people with schizophrenia

Firth, J., Cotter, J., Carney, R., & Yung, A. R. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13772 · Cited by 79 · see citing works

Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia

Zuelli, F. M. D. G. C., & Deakin, J. F. W. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.03.004 · Cited by 85 · see citing works

Tryptophan Metabolism and White Matter Integrity in Schizophrenia

Chiappelli, J., Postolache, T. T., Kochunov, P. V., Rowland, L. M., Wijtenburg, S. A., Shukla, D. K., Tagamets, M. A., Du, X. M., Savransky, A., Lowry, C. A., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.66 · Cited by 84 · see citing works

Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus

Mizuki, Y., Sakamoto, S., Okahisa, Y., Yada, Y., Hashimoto, N., Takaki, M., & Yamada, N. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa097 · Cited by 83 · see citing works

C-Reactive Protein/Albumin and Neutrophil/Albumin Ratios as Novel Inflammatory Markers in Patients with Schizophrenia

Balcioglu, Y. H., & Kirlioglu, S. S. (2020) · Psychiatry Investigation · doi:10.30773/pi.2020.0185 · Cited by 80 · see citing works

Long-term pathological consequences of prenatal infection: beyond brain disorders

Labouesse, M. A., Langhans, W., & Meyer, U. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00087.2015 · Cited by 78 · see citing works

The Emerging Immunogenetic Architecture of Schizophrenia

Pouget, J. G. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby038 · Cited by 75 · see citing works

Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis

Patlola, S. R., Donohoe, G. J., & McKernan, D. P. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.01.042 · Cited by 75 · see citing works

A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue

Hoseth, E. Z., Ueland, T., Dieset, I., Birnbaum, R., Shin, J. H., Kleinman, J. E., Hyde, T. M., Mørch, R. H., Hope, S., Lekva, T., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw183 · Cited by 77 · see citing works

Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis

Park, S., & Miller, B. J. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.012 · Cited by 75 · see citing works

Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis

Goldsmith, D. R., Haroon, E., Miller, A. H., Addington, J., Bearden, C. E., Cadenhead, K., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.11.315 · Cited by 74 · see citing works

Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study

Martinuzzi, E., Barbosa, S., Daoudlarian, D., Ali, W. B. H., Gilet, C., Fillatre, L., Khalfallah, O., Troudet, R., Jamain, S., Fond, G. B., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0366-5 · Cited by 74 · see citing works

Interaction of BDNF with cytokines in chronic schizophrenia

Zhang, X. Y., Tan, Y., Chen, D., Tan, S., Yang, F., Wu, H. E., Zunta‐Soares, G. B., Huang, X., Kosten, T. R., & Soares, J. C. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.09.014 · Cited by 72 · see citing works

The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis

Johnsen, E., Fathian, F., Kroken, R. A., Steen, V. M., Jørgensen, H. A., Gjestad, R., & Løberg, E. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0769-x · Cited by 72 · see citing works

Thyroid hormones in persons with schizophrenia: A systematic review and meta-analysis

Misiak, B., Stańczykiewicz, B., Wiśniewski, M., Bartoli, F., Carrà, G., Cavaleri, D., Samochowiec, J., Jarosz, K., Rosińćzuk, J., & Frydecka, D. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110402 · Cited by 71 · see citing works

Changes in serum TNF-α, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge

Luo, Y., He, H., Zhang, J., Ou, Y., & Fan, N. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.01.003 · Cited by 70 · see citing works

Neuroinflammation in psychiatric disorders: An introductory primer

Dunn, G. A., Loftis, J. M., & Sullivan, E. L. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172981 · Cited by 73 · see citing works

Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder

Miller, B. J., & Goldsmith, D. R. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200015 · Cited by 71 · see citing works

The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia

Chase, K. A., Cone, J. J., Rosen, C., & Sharma, R. P. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0866-x · Cited by 69 · see citing works

Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model

McGinnis, G. J., Friedman, D. J., Young, K. H., Torres, E. R. S., Thomas, C. R., Gough, M. J., & Raber, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13551 · Cited by 69 · see citing works

Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control Study of the ALSPAC Longitudinal Birth Cohort

English, J. A., Lopez, L. M., O’Gorman, A., Föcking, M., Hryniewiecka, M., Scaife, C., Sabherwal, S., Wynne, K. J., Dicker, P., Rutten, B. P. F., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx075 · Cited by 69 · see citing works

A loss of mature microglial markers without immune activation in schizophrenia

Snijders, G. J. L., van Zuiden, W., Sneeboer, M. A. M., van Berlekom, A. B., van der Geest, A. T., Schnieder, T. P., MacIntyre, D. J., Hol, E. M., Kahn, R. S., & de Witte, L. D. (2021) · Glia · doi:10.1002/glia.23962 · Cited by 66 · see citing works

Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology

Miller, B. J., & Goldsmith, D. R. (2019) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2019.100006 · Cited by 66 · see citing works

Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone

Noto, C. D. S., Ota, V., Gadelha, A., Noto, M. N., Barbosa, D. S., Bonifácio, K. L., Nunes, S. O. V., Cordeiro, Q., Belangero, S. I., Bressan, R. A., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.003 · Cited by 67 · see citing works

Investigating the neuroimmunogenic architecture of schizophrenia

Birnbaum, R., Jaffe, A. E., Chen, Q., Shin, J. H., BrainSeq Consortium, Schubert, C. R., O'Donnell, P., Quan, J., Wendland, J. R., Xi, H. S., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.89 · Cited by 67 · see citing works

Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine Receptor

Zuelli, F. M. D. G. C., Brognara, F., Quirino, G. F. S., Hiroki, C. H., Fais, R. S., Del‐Ben, C. M., Ulloa, L., Salgado, H. C., Kanashiro, A., & Loureiro, C. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00618 · Cited by 69 · see citing works

Persistent psychotic symptoms following COVID-19 infection

Lim, S. T., Janaway, B., Costello, H., Trip, A., & Price, G. W. (2020) · BJPsych Open · doi:10.1192/bjo.2020.76 · Cited by 66 · see citing works

Effects of depression on the cytokine profile in drug naïve first-episode psychosis

Noto, C. D. S., Ota, V., Santoro, M. L., Ortiz, B. B., Rizzo, L. B., Higuchi, C. H., Cordeiro, Q., Belangero, S. I., Bressan, R. A., Gadelha, A., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.026 · Cited by 65 · see citing works

Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index

Haring, L., Koido, K., Vasar, V., Leping, V., Zilmer, K., Zilmer, M., & Vasar, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.027 · Cited by 63 · see citing works

Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia

Balõtšev, R., Koido, K., Vasar, V., Janno, S., Kriisa, K., Mahlapuu, R., Ljubajev, Ü., Parksepp, M., Veiksaar, P., Volke, V., et al. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.05.010 · Cited by 65 · see citing works

Inflammation in first‐episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta‐analysis

Dunleavy, C., Elsworthy, R. J., Upthegrove, R., Wood, S. J., & Aldred, S. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13416 · Cited by 169 · see citing works

High‐quality large‐scale longitudinal studies with detailed multimodal immunological phenotyping are warranted to disentangle the involvement of the immune system in psychosis

Benros, M. E. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13458 · Cited by 1 · see citing works

Clinical Relevance of Peripheral Interleukins in Drug-Naive First-Episode Psychosis: Symptom-Specific Associations from the PANSS Dimensions

Binić, I., Petrovic, J., Žikić, O., Tošić-Golubović, S., Djordjevic, V., Stevanovic, M., Krtinić, D., & Apostolovic, M. A. (2025) · Brain Sciences · doi:10.3390/brainsci15090932 · Cited by 6 · see citing works

Cytokine profile in drug-naïve, first episode patients with psychosis

Petrikis, P., Voulgari, P. V., Tzallas, A. T., Archimandriti, D. T., Skapinakis, P., & Mavreas, V. G. (2015) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2015.06.011 · Cited by 28 · see citing works

Active psychosis and pro-inflammatory cytokines in first-episode of psychosis

de Santayana, G. P., Juncal‐Ruíz, M., Vázquez-Bourgón, J., Riesco-Dávila, L., de la Foz, V. O., Pelayo‐Terán, J. M., López‐Hoyos, M., & Crespo‐Facorro, B. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.060 · Cited by 16 · see citing works